Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Protein Degradation and Inhibitors.
Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial
Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial
Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia
IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) <i>KMT2Ar</i> Acute Leukemia
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
MEN1 mutations mediate clinical resistance to menin inhibition
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
Entospletinib with decitabine in acute myeloid leukemia with mutant <i>TP53</i> or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed <i>IDH2</i>-mutant AML
Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
Revumenib Monotherapy in Patients with Relapsed/Refractory <i>KMT2Ar</i> Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
Revumenib Monotherapy in Patients with Relapsed/Refractory <i>KMT2Ar</i> Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Targeting <i>RARA</i> overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with <i>KMT2A</i>-Rearranged or <i>NPM1</i> Mutant AML: Updated Results of a Phase (Ph) 1 Study
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
Pevonedistat with azacitidine in older patients with <i>TP53</i>-mutated AML: a phase 2 study with laboratory correlates
Ivosidenib in patients with <i>IDH1</i>-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML